Morgan Stanley Humacyte, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Humacyte, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,376,595 shares of HUMA stock, worth $2.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,376,595

Previous 580,370 137.19%

Holding current value

$2.38 Million

Previous $992,000 190.02%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$1.15 - $2.77 $915,658 - $2.21 Million	796,225 Added 137.19%	1,376,595 $2.88 Million
Q1 2025 May 15, 2025	SELL	$1.71 - $5.18 $60,557 - $183,444	-35,414 Reduced 5.75%	580,370 $992,000
Q4 2024 Feb 14, 2025	BUY	$3.46 - $5.81 $195,389 - $328,096	56,471 Added 10.1%	615,784 $3.11 Million
Q3 2024 May 14, 2025	BUY	$5.11 - $9.46 $1.82 Million - $3.37 Million	356,182 Added 175.35%	559,313 $3.04 Million
Q3 2024 Nov 14, 2024	BUY	$5.11 - $9.46 $1.82 Million - $3.37 Million	356,182 Added 175.35%	559,313 $3.04 Million
Q2 2024 May 14, 2025	SELL	$2.87 - $9.1 $1.18 Million - $3.76 Million	-412,653 Reduced 67.01%	203,131 $975,000
Q2 2024 Oct 17, 2024	BUY	$2.87 - $9.1 $180,236 - $571,480	62,800 Added 44.75%	203,131 $975,000
Q2 2024 Aug 14, 2024	BUY	$2.87 - $9.1 $180,236 - $571,480	62,800 Added 44.75%	203,131 $975,000
Q1 2024 Oct 17, 2024	SELL	$2.57 - $4.84 $161,396 - $303,952	-62,800 Reduced 30.92%	140,331 $436,000
Q1 2024 Aug 16, 2024	SELL	$2.57 - $4.84 $34,422 - $64,826	-13,394 Reduced 8.71%	140,331 $436,000
Q1 2024 May 15, 2024	SELL	$2.57 - $4.84 $34,422 - $64,826	-13,394 Reduced 8.71%	140,331 $436,000
Q4 2023 Aug 16, 2024	SELL	$1.99 - $3.12 $98,317 - $154,146	-49,406 Reduced 24.32%	153,725 $436,000
Q4 2023 Feb 13, 2024	BUY	$1.99 - $3.12 $150,085 - $235,310	75,420 Added 96.32%	153,725 $436,000
Q3 2023 Nov 15, 2023	SELL	$2.75 - $4.48 $39,503 - $64,355	-14,365 Reduced 15.5%	78,305 $229,000
Q2 2023 Aug 14, 2023	BUY	$2.86 - $4.97 $48,691 - $84,614	17,025 Added 22.51%	92,670 $265,000
Q1 2023 May 15, 2023	BUY	$2.11 - $3.25 $56,096 - $86,404	26,586 Added 54.19%	75,645 $233,000
Q4 2022 Feb 14, 2023	BUY	$2.02 - $3.62 $4,223 - $7,569	2,091 Added 4.45%	49,059 $103,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $5.14 $8,326 - $35,080	6,825 Added 17.0%	46,968 $153,000
Q2 2022 Oct 27, 2022	SELL	$3.21 - $7.86 $7,896 - $19,335	-2,460 Reduced 5.77%	40,143 $129,000
Q2 2022 Aug 15, 2022	SELL	$3.21 - $7.86 $7,896 - $19,335	-2,460 Reduced 5.77%	40,143 $129,000
Q1 2022 Oct 27, 2022	BUY	$4.65 - $7.4 $11,439 - $18,204	2,460 Added 6.13%	42,603 $300,000
Q1 2022 May 13, 2022	SELL	$4.65 - $7.4 $228,845 - $364,183	-49,214 Reduced 53.6%	42,603 $300,000
Q4 2021 Feb 14, 2022	BUY	$7.25 - $11.6 $141,186 - $225,898	19,474 Added 26.92%	91,817 $666,000
Q3 2021 Nov 15, 2021	BUY	$9.21 - $16.99 $666,279 - $1.23 Million	72,343 New	72,343 $840,000

Others Institutions Holding HUMA

# of Institutions

166

Shares Held

54.3M

Call Options Held

1.1M

Put Options Held

808K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $178M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account